The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 05, 2017

Filed:

Mar. 17, 2014
Applicants:

The Translational Genomics Research Institute, Phoenix, AZ (US);

Mayo Foundation for Medical Education and Research, Rochester, MN (US);

Inventors:

Mitesh Jivraj Borad, Scottsdale, AZ (US);

David Craig, Phoenix, AZ (US);

John Carpten, Phoenix, AZ (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A01N 43/58 (2006.01); A01N 43/60 (2006.01); A61K 31/50 (2006.01); A61K 31/495 (2006.01); A61K 31/517 (2006.01); A61K 31/5377 (2006.01); C12Q 1/68 (2006.01); A61K 9/00 (2006.01); A61K 31/5025 (2006.01); A61K 31/506 (2006.01);
U.S. Cl.
CPC ...
A61K 31/517 (2013.01); A61K 9/0053 (2013.01); A61K 31/506 (2013.01); A61K 31/5025 (2013.01); A61K 31/5377 (2013.01); C12Q 1/6886 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01);
Abstract

Methods of selecting a chemotherapy regimen for treatment of cancer in a patient are disclosed. A patient genetic sample from a bilary cancer such as cholangiocarcinoma is analyzed for a mutation in ERRFI1 and a chemotherapeutic agent is selected as a result of the analysis. If a mutation in ERRFI1 is present, treatment with an inhibitor of Epidermal Growth Factor Receptor (EGFR) is shown to have inhibitory effects on tumor growth. In this manner, the chemotherapy regimen is targeted to a given mutation in a patient's cancer.


Find Patent Forward Citations

Loading…